The user-centric XR Glasses create unparalleled, ultra-comfortable massive-screen enjoyment for home viewers, avid gamers and users on-the-move.

IRVINE, Calif., Nov. 9, 2023 /PRNewswire/ — RayNeo™, an industry leader in consumer-grade augmented reality (AR) innovation, has launched its latest RayNeo Air 2 XR glasses for the global markets. Crafted with a user-centric principle, the RayNeo Air 2 delivers cinema-grade vibrant visuals, immersive private audio experiences, and a wealth of customizable features to match users’ preferences. All of this is elegantly encased in a comfortable and stylish design.

RayNeo Air 2

The RayNeo Air 2 marks RayNeo’s latest achievement in consumer-focused wearable displays, following the groundbreaking success of the RayNeo X2 true AR glasses — the world’s first binocular full-color MicroLED optical waveguide AR glasses.

Riding the wave of display breakthroughs, the RayNeo Air 2 aims to enhance the holistic user experience of XR wearables. Whether you want unrestricted, cinema-quality viewing from any position, to create a personal virtual workspace in a crowded environment, or to dive into seamless gaming adventures, the RayNeo Air 2 opens up a world of endless possibilities for you.

Ultra-Crisp, Ultra-Brilliant, Unparalleled Audiovisuals

The RayNeo Air 2 presents exceptional visuals while using less power and lighter display panels, compared with its predecessor, the GLOMO award-winning TCL NXTWEAR S. Harnessing Sony’s latest 0.55-inch Micro OLED screens, RayNeo Air 2’s dual Full HD displays unfold an expansive 46° field of view (FOV) with a crystal-clear clarity of 49 pixels-per-degree (PPD). The glasses bring to users a vivid, detailed, and portable visual experience, equivalent to watching a 201-inch virtual screen from six meters away, akin to being in an immersive movie theater.

Thanks to RayNeo’s TCL-backed cutting-edge display technology, the RayNeo Air 2 boasts an industry-leading image brightness of up to 600 nits. With a sharpness greater than 0.8 MTF, a 108% sRGB color range, and an impressive 100,000:1 contrast ratio, these glasses transform your real environment into a virtual cinematic studio, fully unleashing XR technology’s potential.

Enjoy remarkable dynamic surround immersion powered by RayNeo’s latest audio technologies. Engineered with dual super-linear stereo speakers, the well-calibrated sound system delivers a refined bassline for immersive jamming sessions anywhere, anytime. As a pioneer in applying advanced anti-leakage sound techniques to XR glasses, RayNeo introduces an enhanced "Whisper Mode 2.0" version for discreet listening. Enhanced acoustic phase cancellation technology guarantees your privacy while creating a disturbance-free environment for those around you.

Superior Comfort for Extended Wear

Encased in a sleek and lightweight body, the device is around 15% lighter than the TCL NXTWEAR S. Exclusive air-cushion nose pads create a feather-like touch to your nose. The weight distribution is meticulously optimized to reduce pressure on the face, and the enhanced thermal design ensures your forehead remains comfortable even after prolonged use, whether you’re lying in bed or resting in an airplane seat.

Innovatively, the glasses offer 9 different wearing options to fit a wide range of face shapes. This versatility is achieved with the nose pads’ "front," "middle," and "back" settings, along with three sets of vertical adjustment (for a total of 10°) for the temples, all easily adjustable at your fingertips.

Moreover, the RayNeo Air 2 has attained the industry’s top-level eye protection certification from TÜV Rheinland, covering Eye Comfort, Low Blue Light, and Flicker Free. Its advanced vision protection techniques minimize eye fatigue and dizziness, providing users with peace of mind as they relish immersive visuals. 

Revolutionary Gaming Companion

Elevate your gaming experience to a whole new level with the RayNeo Air 2, which features a blazing-fast 120Hz refresh rate for silky-smooth gameplay. With simple setups, the glasses can connect to  a host of gaming devices, including gaming phones, PCs, and consoles such as the Steam Deck, Sony PlayStation, and Microsoft Xbox.

There’s also exciting news for Nintendo Switch enthusiasts with the arrival of JoyDock – the first-of-its-kind, all-in-one adapter customized for this beloved console. When paired with the RayNeo Air 2, JoyDock seamlessly enhances your Nintendo Switch gaming experience, offering immersive thrills on a colossal 201-inch screen. Equipped with a robust 10,000mAh battery capacity, it effortlessly powers both the console and the glasses during hours-long gameplay. Say goodbye to uncomfortable positions, bid farewell to battery anxiety, and take your Switch with you everywhere, thanks to the chic, starship-inspired frame tailor-made for the console that allows for an easy, one-slide attachment.

Personalized Features Tailored to Your Needs

Recognizing valuable feedback from our users, RayNeo has incorporated a personal touch to the latest RayNeo Air 2 glasses. For the first time, these glasses offer unprecedented color adjustment flexibility to users. Wearers can simply fine-tune the glasses’ display settings on the "RayNeo XR" app, including saturation, temperature, and color tone, to align with their viewing preferences.

Having concerns about myopia issues? RayNeo has teamed up with Lensology to provide customized, magnetic correction lens solutions for users worldwide. With convenient online ordering and efficient global delivery right to your doorstep, RayNeo ensures that your specifications are met with precision and care.

Pricing and Availability

The RayNeo Air 2 is now available on the RayNeo Amazon US store at a recommended retailer price (RRP) of $379.

The RayNeo Air 2 will also be available from Q4 2023 through RayNeo’s regional channels and authorized retail partner stores across the globe, including North America, Europe, Asia Pacific, and the Middle East.

The JoyDock is expected to be on sale on Amazon US in the first half of December 2023, at the RRP of $99.

To learn more about the RayNeo Air 2, please visit: https://www.rayneo.com/

About RayNeo

RayNeo™, incubated by TCL Electronics (1070.HK), is an industry leader in consumer-grade AR innovation, developing some of the world’s most revolutionary AR consumer hardware, software, and applications. RayNeo specializes in the research and development of AR technologies with industry-leading optics, display, algorithm, and device manufacturing.

Established in 2021, RayNeo has launched the world’s first full-color Micro-LED optical waveguide AR glasses, achieving several technology breakthroughs in the industry. Alongside winning the "Best Connected Consumer Device" at MWC’s Global Mobile Awards (GLOMO) 2023 with NXTWEAR S, RayNeo also developed the innovative consumer XR wearable glasses, RayNeo Air 2, featuring top-tier, cinematic audiovisual experiences with ultimate comfort.

Source : RayNeo Air 2 XR Glasses Revolutionize Wearable Display User Experience, Launched on Amazon US

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE and JAKARTA, Indonesia, Nov. 9, 2023 /PRNewswire/ — Singapore Post Limited (SingPost) and Pos Logistics, have entered a memorandum of understanding (MOU) to advance cross-border logistics and eCommerce exports for Indonesian eRetailers.

With an expected annual growth rate of 10.41% for the next 5 years in Indonesia, it is expected that there will be 244.7 million eCommerce users and a projected market volume of US$67.30 billion by 2027.[1]

This partnership will explore ways to create an efficient supply chain from Indonesia to Europe, Australia, the Middle East, and the rest of Asia. The provision of services will also include linehaul and warehousing, as well as route optimisation.

Mr Ardian Cholid, CEO, Pos Logistics said, "As our continuous support to Indonesia eCommerce players in going global, we are confident to partner with SingPost where POS Logistics domestic capability and SingPost International network would greatly advanced our export capability resulting important commercial expansion for both sides."

Mr Li Yu, CEO International, SingPost said, "We are excited to partner Pos Logistics. With SingPost postal network and commercial trade lanes, we hope to help the Indonesian eRetailers grow their businesses with streamlined logistics processes, expanded market reach globally and enhanced delivery with scale and speed."

The first export shipment has successfully been delivered from Jakarta to France in early November. More European destinations are in the line-up as the festive season approaches.

Personnel in the photo are as follows: From left: Mr Faizal Rochmad Djoemadi, President Director PT Pos Indonesia, Mr Li Yu, Chief Executive Officer, International, Singapore Post, Mr Ardian Cholid, President Director PT Pos Logistik Indonesia, Mr Noel Singgih, Group Chief Information Officer, Singapore Post

About Singapore Post Limited

Singapore Post (SingPost) is a leading eCommerce logistics provider in Asia Pacific. The portfolio of businesses spans from national and international postal services to warehousing and fulfilment, last mile delivery and international freight forwarding, serving customers in more than 220 markets. Headquartered in Singapore, SingPost has over 5,000 employees, with offices in 13 markets. Since its inception in 1858, the Group has evolved and innovated to bring about best-in-class postal and integrated logistics solutions, making every delivery count for people and planet. 

About POS Logistics

PT Pos Logistik Indonesia is a 3rd Party Logistics Solutions provider that offers logistics solutions for the B2B segment and provides retail logistics cargo services for the B2C segment. The company’s target markets include automotive, consumer goods, chemicals, pharmaceuticals, fashion, postal & courier services, government, telecommunications, mining, oil & gas, agribusiness, and heavy equipment.

As a subsidiary of PT Pos Indonesia (Persero), this company is expected to operate independently to maximize logistics business opportunities in Indonesia. Not only that, but the presence of Pos Logistik also serves as an opportunity to leverage the Pos Indonesia network, which has 33,000 sales points and 4,367 networks.

[1] Source: https://www.statista.com/outlook/dmo/ecommerce/indonesia

Source : SingPost Partners Pos Logistics to Further Growth of eCommerce Exports in Indonesia

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Feasibility Project Awarded VA Technology Transfer Program BRAVE Funding

SALT LAKE CITY, Nov. 9, 2023 /PRNewswire/ — DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced a basic science Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to assess the feasibility of using DiscGenics’ proprietary Discogenic Cells with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure (eDAPS).

eDAPS seeded with Discogenic Cells from DiscGenics.

eDAPS, devised by researchers at the VA and the University of Pennsylvania, are living tissue-engineered resorbable polymer vertebral disc implants that mimic the native structure and function of the disc and are intended to replace degenerated discs in patients with late-stage intervertebral disc (IVD) degeneration.

Discogenic Cells are a manufactured, live progenitor cell population derived from donated adult human intervertebral disc tissue and are used as the therapeutic engine in DiscGenics’ mild to moderate lumbar degenerative disc disease product candidate, IDCT (rebonuputemcel).

Through this ongoing collaboration, researchers have determined that eDAPS manufactured using DiscGenics’ proprietary nucleus pulposus and annulus fibrosus derived Discogenic Cells are mechanically and biochemically distinct from eDAPS using mesenchymal stem cells (MSCs).

"Discogenic Cell-derived eDAPS are a promising translational development, as we can now culture tissue-engineered discs at a scale appropriate for human cervical disc replacement using a translatable human nucleus pulposus and annulus fibrosus cell source," said VA Principal Investigator, Sarah Gullbrand, Ph.D., who is a Research Scientist in the Translational Musculoskeletal Research Center at the Corporal Michael J. Crescenz VA Medical Center, with a co-appointment as a Research Assistant Professor in the McKay Orthopaedic Research Laboratory in the Department of Orthopaedic Surgery at the University of Pennsylvania.

This project has been awarded BRAVE Funding by the VA Technology Transfer Program (TTP), which will further research of this combined technology and support a large animal study of Discogenic Cell-derived implants. The BRAVE Funding is intended to continue innovation of VA-owned technologies and better position the technology for partnering with companies for the benefit of the veteran and broader use in the United States.

"DiscGenics is proud to be collaborating with the VA, Dr. Gullbrand, Dr. Robert Mauck, and their team at the University of Pennsylvania on this important project," said Flagg Flanagan, CEO and Chairman of DiscGenics. "Back pain arising from IVD degeneration is one of the most common causes of limited function in adults. DiscGenics is developing IDCT for mild to moderate lumbar degenerative disc disease, but we recognize that for many patients whose disease has progressed to the severe stage, surgical intervention may be necessary. Utilizing our Discogenic Cell platform to generate implants that could replace degenerated discs would significantly broaden the treatment options for this patient population."

Kevin T. Foley, M.D., Chief Medical Officer of DiscGenics added, "A biologic disc replacement in lieu of existing mechanical devices would continue to change the paradigm of spine care away from a device-centric model to one of disease modification through biologic and cell-based treatments."

About DiscGenics

DiscGenics is a privately held, late-stage clinical, biopharmaceutical company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, mild to moderate lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. IDCT has been granted regenerative medicine advanced therapy (RMAT) and Fast Track designations by the U.S. Food and Drug Administration. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics has a unique opportunity to offer a non-surgical, potentially regenerative solution for the treatment of patients suffering from the debilitating effects of back pain. For more information, visit discgenics.com. 

Photo – https://mma.prnasia.com/media2/2271225/DiscGenics_eDAPS_single.jpg?p=medium600
Logo – https://mma.prnasia.com/media2/561675/DiscGenics_Logo.jpg?p=medium600

Source : DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.

Dr. Wu was invited to participate in Session 3: Clinical Immunology and Immunotherapy Updates, with a presentation titled "Efficacy and Safety of Targeting PD-L1 with Monoclonal Antibodies".

Ascletis recently announced positive interim data from the Phase IIb expansion cohort of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of CHB. The interim analysis included 25 patients who completed 24-week treatment (19 patients in ASC22 cohort and 6 patients in placebo cohort). Topline results indicated that in ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24-week treatment. In contrast, there were no patients (0/6, 0%) achieving HBsAg loss at the end of 24-week treatment in the placebo cohort. ASC22 was generally safe and well tolerated. Most of ASC22 drug related adverse effects were Grade 1 or 2.

Representatives from companies including Roche, GSK, Gilead, Immunocore, VIR, Arbutus, Aligos and experts from National Institutes of Health, University of Oxford, Massachusetts General Hospital, Johns Hopkins University, Lyon I University, University of Hong Kong, Toronto Centre for Liver Disease, Emory University Center for AIDS Research, Harvard Medical School, Northwestern University, University of Milan also joined the meeting. Ascletis is the only Chinese biotech company which presented at the meeting.

CHB remains to be a significantly unmet medical need globally, with approximately 86 million people in China and 1.59 million people in the U.S. infected with hepatitis B virus (HBV) [1].

"It’s a great honor to be invited to the 10th International Workshop on HBV Cure 2023 and share our latest progress in developing the immune checkpoint inhibitor for functional cure of CHB with the global industry. ASC22 is the most advanced clinical-stage immunotherapy in the world for CHB functional cure, i.e. HBsAg loss, through blocking PD-1/PD-L1 pathway. The number of patients with HBsAg ≤100 IU/mL is huge, which accounts for approximately 15%-22% of the total patient population [2][3]. We will continue to accelerate the clinical study of ASC22 and benefit CHB patients." said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis.

[1]Lim J K, Nguyen M H, Kim W R, et al. Prevalence of Chronic Hepatitis B Virus Infection in the United States [J]. The American journal of gastroenterology 2020, 115(9): 1429-38.

[2]Xie, Y., Li, M., Ou, X. et al. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 56, 856–867 (2021).

[3]Coffin, Carla S et al. "Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA)." Viruses vol. 14,12 2668. 29 Nov. 2022

About The International Workshop on HBV Cure

Since 2014, the International Workshop on HBV Cure has been a scientific platform acting as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people live with hepatitis B (HBV). The purpose of the workshop is to inform the participants about the developments in the work to find a cure for HBV. The meeting is highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research. The 10th International Workshop on HBV Cure 2023 took place as a live workshop on 8 November 2023 in Boston, United States.

About Ascletis

Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has multiple drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (CHB functional cure), ASC40 (acne), ASC40 (recurrent glioblastoma), ASC40 (NASH), ASC41 (NASH) and ASC61 (advanced solid tumors).

For more information, please visit www.ascletis.com.

Source : Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SYDNEY, Nov. 9, 2023 /PRNewswire/ — Great Place To Work®, the global authority on workplace culture will honor 50 companies in the country as the Best Workplaces™ for Women 2023 in Australia. The companies were shortlisted using rigorous analytics and confidential employee feedback.

The Best Workplaces for Women list is determined using Great Place To Work’s For All™ methodology to evaluate hundreds of Certified™ Great Place To Work organisations across Australia.

The Great Place To Work Trust Index™ survey enables employees to share confidential quantitative and qualitative feedback about their organisation’s culture by responding to 60 statements on a 5-point scale and answering two open-ended questions.

Collectively, these statements describe a great employee experience, defined by high levels of trust, respect, credibility, fairness, pride, and camaraderie. In addition, companies provide organisational data like size, location, industry, and the number of women in the workforce and management positions.
 
"The Best Workplaces for Women list is based on data representative of over 40,000 employee voices from women in Great Place To Work Certified™ organisations across Australia, said Mr Roland Wee, Managing Director of Great Place To Work Australia." 

"We have indeed made great strides in closing gender disparity in Australian companies and the recent legislation to publish gender pay gap from 2024 is yet another step in the right direction.

"However, as long as we rely on legislation to enforce it, we will never be able to reach true equality. Great Place To Work Certified companies must lead the way in making the workplace fairer and more equitable for all.

"We congratulate the companies listed on The Best Workplaces for Women 2023 List and they are indeed the best-of-the-best, as validated by the voices of their employees", said Mr Wee.

ENDS

About Great Place To Work Certification

Great Place To Work CertificationTM is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place To Work Certification is recognised worldwide by employees and employers alike and is the global benchmark for identifying and recognising outstanding employee experience. Every year, more than 10,000 companies across 97 countries apply to earn Great Place To Work Certification. 

About Great Place To Work

Great Place To Work is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting and insights they need to make data-driven people decisions. Everything they do is driven by the mission to build a better world by helping every organisation become a great place to work For All.

Learn more at https://greatplacetowork.com.au/ and on Facebook [https://www.facebook.com/greatplacetoworkAU] , LinkedIn [https://www.linkedin.com/company/great-place-to-work-institute-australia/] & Instagram [https://www.instagram.com/gptw_au]

Best Workplaces™ for Women list 2023 – 50 organisations have been listed, and appear published in alphabetical order:

AbbVie

Alluvium Group

Arjo Australia

Avenue Dental

BeiGene Australia Pty Ltd   

Berkley Insurance Company

BGL Corporate Solutions Pty Ltd

Blue Connections IT

Boston Scientific

Bristol Myers Squibb Australia

Carlisle Homes

Carnival Australia

Cashrewards

Cisco

Collar

Ecosure

EML

Frontline Recruitment Group and Express Employment Professionals Australia & New Zealand

General Mills

Greenstone Financial Services

Harrison.ai

Henry Schein Australia

Hub Australia

InfoTrack

Insight Enterprises Australia

Intuit Quickbooks Australia

Invest Blue

Jaybro Group

Kelly+Partners Chartered Accountants

Lockton Companies Australia

Mantel Group

Mastercard Australia

NeuroRehab Allied Health Network

Nous Group

Nurse Next Door Home Care Services

OzHarvest

PageGroup Australia

Queensland Country Bank

Ralph Lauren

REA Group

Reckitt Australia & New Zealand

Robert Half

Sandoz

Slalom

Smokeball

Sparro & Jack Nimble

Starlight Children’s Foundation

Swisse Wellness (H&H Group)

Uber Australia PTY LTD

Zoetis Australia

Source : Best Workplaces for Women in 2023 announced by Great Place To Work Australia

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Visitation Revenue Adjusted EBITDA All Surpassed 2019
Solid Market Share and Margin

HONG KONG, Nov. 9, 2023 /PRNewswire/ — MGM China Holdings Limited ("MGM China" or the "Company"; SEHK Stock Code: 2282) today announced the selected unaudited financial data of the Company and its subsidiaries (the "Group") for the three and nine months ended September 30, 2023.

The Group is pleased to see a solid recovery in Macau since the beginning of the year. Macau saw average daily visitor arrival for the third quarter reach 90,025, up by 22% from the second quarter, recovered to 84% of pre-COVID levels of the same period in 2019.

Visitation recovery has boosted gross gaming revenue (GGR). Industry GGR rose 7% quarter-to-quarter to MOP531 million per day, representing 69% of pre-COVID levels, compared to 62% recovery in the second quarter. Industry EBITDA in the third quarter was recovered to an estimated 80% of the same period in 2019.

MGM China continues to outperform industry recovery and grow from 2019. Third-quarter property visitation was 121% of the same period in 2019. Daily GGR was 101% and mass GGR (including slot) was 137% of 2019. Net revenue of the Group grew by 10% to HK$6.4 billion for the quarter compared to 2019. The Group reported adjusted EBITDA of HK$1.9 billion for the quarter, 122% of 2019, consistently outperforming the market. We maintained market share at 14.3% for the quarter, up from 9.5% in FY2019. MGM MACAU market share was 6.4% and MGM COTAI market share was 7.9%. Adjusted EBITDA margin for the quarter also grew 280 basis points to 29.6% from 26.8% in 2019, with a mass-focused business and continuous improvement in operational efficiency. On a property basis, MGM MACAU recorded revenue of HK$2.9 billion for the quarter (3Q19: HK$2.9 billion) and an adjusted EBITDA of HK$880.5 million (3Q19: HK$855.6 million). MGM COTAI had revenue of HK$3.5 billion for the quarter (3Q19: HK$2.8 billion) and an adjusted EBITDA of HK$1.0 billion (3Q19: HK$692.9 million). The Group maintained a healthy financial position. As of September 30, 2023, the Group had a total liquidity of approximately HK$18.2 billion, comprised of cash, cash equivalents and undrawn revolver.

The Group experienced a robust Golden Week in October, during which market GGR in the month reached a post-pandemic high of MOP19.5 billion, reaching 74% of 2019’s and implying a daily run-rate of MOP629 million.

MGM China market share rose to 15.5% in October, and 14.8% year to date.

Kenneth Feng, President and Executive Director of MGM China said: "We are excited about the recovery in Macau, along with the diversification development of the city. We will continue investing in the gaming floor to enhance table yield. At the same time, we are committed to bringing in more unique integrated tourism experiences to attract international visitors."

During the quarter, MGM had hosted a variety of exciting events in Macau. In August, MGM collaborated with Robb Report Hong Kong to present MGM x RR1 Culinary Masters Macau for a four-day deluxe dining extravaganza – where a team of international and local award-winning chefs came together to create gourmet meals featuring the world’s top wines and delicacies for international guests from over 10 countries. The event fully demonstrates Macau’s unique position as a UNESCO Creative City of Gastronomy and its cultural attributes fusing Chinese and Western elements.

Also in August, Asian renowned band Mayday dazzled in a one-night exclusive concert at MGM COTAI with their megahits in their first outdoor performance in Macau. The concert took place against the stunning backdrop of MGM COTAI’s jewelry box design, creating a mesmerizing night view of the skyline, as another testament to MGM’s dedication to providing diverse cultural tourism experiences.

As a supporter of cultural tourism, MGM again collaborated with world-renowned Portuguese artist Joana Vasconcelos to present a large-scale art installation Valkyrie Miss Dior at MGM COTAI. While at the MGM Theater, the Group presented the signature exhibition titled To Infinity and Beyond, which drew on the avant-garde concept of "ART-TECH-TAINMENT" to showcase artworks created since the 1960s by prestigious Chinese contemporary artists Hsiao Chin, as an initiative to support the city-wide international event Art Macao organized by the Macao SAR government.

At MGM MACAU, we hosted an art appreciation exhibition with Buccellati in September at the Grande Praca. The Timeless Beauty with Century-Old Craftsmanship exhibition showcased some exquisite collections and demonstrated the exceptional craftsmanship of the refined Italian jewelry maker to the public in Macau.

"MGM has always trailblazed the innovative fusion of ‘Art+Tourism’, creating art and cultural programs of international standard that seamlessly integrate into our daily lives. We are committed to developing Macau into a global and diversified tourist destination through our concession commitments," said Kenneth Feng.

About MGM China Holdings Limited
MGM China Holdings Limited (HKEx: 2282) is a leading developer, owner and operator of gaming and lodging resorts in the Greater China region. We are the holding company of MGM Grand Paradise, SA which holds one of the six gaming concessions to run casino games in Macau. MGM Grand Paradise, SA owns and operates MGM MACAU, the award-winning premium integrated resort located on the Macau Peninsula and MGM COTAI, a contemporary luxury integrated resort in Cotai, which opened in early 2018 and more than doubles our presence in Macau. 

MGM China is majority owned by MGM Resorts International (NYSE: MGM) one of the world’s leading global hospitality companies, operating a portfolio of destination resort brands including Bellagio, ARIA, MGM Grand, Mandalay Bay and Park MGM. For more information about MGM Resorts International, visit the Company’s website at www.mgmresorts.com.

Source : MGM China Reports 2023 Third-Quarter Results

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Nov. 9, 2023 /PRNewswire/ — MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that the Company received a notification letter (the "Notification Letter") from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq’s minimum bid price requirement and that the matter is closed.

As previously disclosed, MMTec, Inc. (the "Company"), received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") on June 27, 2023, indicating that the Company was not in compliance with Nasdaq Rule 5550(a)(2) (the "Bid Price Rule"), as the closing bid price for the Company’s common stock had been below $1.00 per share for the preceding 30 consecutive business days. In accordance with the Nasdaq Listing Rules, the Company was provided a compliance period of 180 calendar days, or until December 26, 2023, to regain compliance with the Bid Price Rule.

On November 7, 2023, the Company received a written notification from the Staff of Nasdaq, notifying the Company that for the preceding 16 consecutive business days, from October 16, 2023 to November 6, 2023, the closing bid price of the Company’s common stock was equal to or greater than the $1.00 per share minimum requirement. Accordingly, the Company has regained compliance with the Bid Price Rule and the matter is closed.

About MMTEC, Inc.

Headquartered in Hong Kong Special Administrative Region, our Company mainly focuses on investment banking and asset management business, providing customers with one-stop and all-round financial services.

More information about the Company can be found at: www.haisc.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "intend", "should", "believe", "expect", "anticipate", "project", "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company’s statements regarding its continued growth, business outlook, and other similar statements are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission, including the Company’s most recently filed Annual Report on Form 20-F and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Source : MMTEC, Inc. Regains Compliance with Nasdaq Minimum Bid Price Deficiency

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network